Literature DB >> 25268766

The anticancer effects of hispolon on lung cancer cells.

Qiuge Wu1, Yan Kang1, Hui Zhang1, Hongmin Wang1, Yuanhua Liu1, Jing Wang2.   

Abstract

Hispolon is isolated from Phellinus igniarius and exhibits antitumor activity. Here, we explored the effects of hispolon on the lung cancer A549 and H661 cells. Cells were incubated with various concentrations of hispolon (0, 5, 10, 20, 40, 80 or 160μM) for 12, 24, 48 or 72h. Cell viability was examined by MTT assay. Cell cycle and apoptosis assay were assessed by flow cytometry. Hispolon decreased cell viability in a dose- and time-dependent manner. The cell cycle distribution showed that hispolon enhanced the accumulations of the cells in G0/G1 phase. Mechanically, hispolon decreased the expression of G1-S transition-related proteins: Cyclin D1, cyclin E, CDK2, CDK4 and CDK6, but increased the expression of CDK inhibitor p21(CIP1) and p27(KIP1). Moreover, hispolon induced cell apoptosis through activation of the mitochondrial pathway, evidenced by the loss of mitochondrial membrane potential, the release of cytochrome c into cytosol, and the cleavage of caspase-9, caspase-3 and poly (ADP-ribose) polymerase (PARP) in hispolon-treated cells. Additionally, hispolon enhanced the expression of p53, specific silencing of which almost completely reversed hispolon-mediated antitumor activity. Moreover, hispolon treatment was more effective on H661 cells than on A549 cells in inhibiting cell viability and inducing cell apoptosis. Our results indicate that hispolon inhibits the cell viability, induces G0/G1 cell cycle arrest and apoptosis in lung cancer cells and p53 plays a critical role in hispolon-mediated antitumor activity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Cell cycle arrest; Hispolon; Lung cancer; Proliferation; p53

Mesh:

Substances:

Year:  2014        PMID: 25268766     DOI: 10.1016/j.bbrc.2014.09.098

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Design, synthesis and in vitro cell-based evaluation of the anti-cancer activities of hispolon analogs.

Authors:  Neduri V Balaji; Modukuri V Ramani; Arabela G Viana; Leticia P Sanglard; Jason White; Vanisree Mulabagal; Crystal Lee; Theophilus J Gana; Nosa O Egiebor; Gottumukkala V Subbaraju; Amit K Tiwari
Journal:  Bioorg Med Chem       Date:  2015-03-21       Impact factor: 3.641

2.  Toxicity and Antigenotoxic Effect of Hispolon Derivatives: Role of Structure in Modulating Cellular Redox State and Thioredoxin Reductase.

Authors:  Pogakula Chethna; Shruti S Iyer; Vishwa V Gandhi; Amit Kunwar; Beena G Singh; Atanu Barik; Neduri V Balaji; Modukuri V Ramani; Gottumukkala V Subbaraju; K Indira Priyadarsini
Journal:  ACS Omega       Date:  2018-06-01

3.  Immunomodulatory Effect of Hispolon on LPS-Induced RAW264.7 Cells and Mitogen/Alloantigen-Stimulated Spleen Lymphocytes of Mice.

Authors:  Eun Kyeong Lee; Eun Mi Koh; Yu Na Kim; Jeongah Song; Chi Hun Song; Kyung Jin Jung
Journal:  Pharmaceutics       Date:  2022-07-06       Impact factor: 6.525

4.  Hispolon suppresses metastasis via autophagic degradation of cathepsin S in cervical cancer cells.

Authors:  Min-Chieh Hsin; Yi-Hsien Hsieh; Po-Hui Wang; Jiunn-Liang Ko; I-Lun Hsin; Shun-Fa Yang
Journal:  Cell Death Dis       Date:  2017-10-05       Impact factor: 8.469

5.  Involvement of Up-regulation of Death Receptors and Bim in Hispolon-mediated TNF-related Apoptosis-inducing Ligand Sensitization in Human Renal Carcinoma.

Authors:  Jung Mi Yun; Kyoung-Jin Min; Taeg Kyu Kwon
Journal:  J Cancer Prev       Date:  2019-09-30

Review 6.  Hispolon: A natural polyphenol and emerging cancer killer by multiple cellular signaling pathways.

Authors:  Ayesha Sarfraz; Azhar Rasul; Iqra Sarfraz; Muhammad Ajmal Shah; Ghulam Hussain; Nusrat Shafiq; Muqaddas Masood; Şevki Adem; Satyajit D Sarker; Xiaomeng Li
Journal:  Environ Res       Date:  2020-08-06       Impact factor: 6.498

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.